Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Forest/Lipha Campral

Executive Summary

FDA approves Campral (acamprosate) July 29 for the treatment of "alcohol dependent individuals seeking to continue to remain alcohol-free after they have stopped drinking." Campral should be used as one part of a comprehensive alcoholism management program that includes "psychosocial support," FDA says in a July 29 "Talk Paper." Forest will launch the drug in the U.S. near the end of the year...

You may also be interested in...



Campral Clears FDA For Alcohol Dependence: Renal Study Part Of Phase IV

Merck KGaA subsidiary Lipha will determine appropriate Campral dosing in patients with severe renal impairment as a postmarketing commitment following FDA approval of the alcoholism therapy

Faster, Better? Fujitsu, Polarisqb 'Quantum-Inspired' Tech Speeds Discovery

Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.

Keeping Track: Oncology Submissions From Blueprint, Y-mAbs, BMS/bluebird; Approvals For BMS’ Reblozyl, LFB’s SevenFact

The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.

Topics

UsernamePublicRestriction

Register

PS044424

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel